|
Absci Corporation (ABSI) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Absci Corporation (ABSI) Bundle
Unser (ABSI) DCF-Taschenrechner (ASSI) ermöglicht es Ihnen, die Bewertung der Absci Corporation mithilfe realer Finanzdaten zu bewerten und gleichzeitig eine vollständige Flexibilität anzubieten, um alle wesentlichen Parameter für verbesserte Projektionen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.1 | 4.8 | 4.8 | 5.7 | 5.7 | 7.4 | 9.7 | 12.5 | 16.3 | 21.2 |
| Revenue Growth, % | 0 | 132.04 | 0.041841 | 20.18 | -0.50461 | 29.93 | 29.93 | 29.93 | 29.93 | 29.93 |
| EBITDA | -5.8 | -12.6 | -99.8 | -91.4 | -95.5 | -7.4 | -9.7 | -12.5 | -16.3 | -21.2 |
| EBITDA, % | -282.77 | -263.35 | -2086.43 | -1589.63 | -1669.41 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .5 | 1.1 | 6.7 | 13.0 | 14.0 | 5.2 | 6.7 | 8.7 | 11.3 | 14.7 |
| Depreciation, % | 23.83 | 23.66 | 139.15 | 226.85 | 244.82 | 69.5 | 69.5 | 69.5 | 69.5 | 69.5 |
| EBIT | -6.3 | -13.7 | -106.4 | -104.4 | -109.5 | -7.4 | -9.7 | -12.5 | -16.3 | -21.2 |
| EBIT, % | -306.6 | -287.01 | -2225.58 | -1816.48 | -1914.24 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 13.1 | 69.9 | 252.6 | 164.4 | 97.7 | 7.4 | 9.7 | 12.5 | 16.3 | 21.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .2 | 1.6 | 1.4 | 1.6 | 2.2 | 2.1 | 2.7 | 3.5 | 4.5 | 5.9 |
| Account Receivables, % | 10.78 | 33.35 | 29.8 | 26.97 | 38.28 | 27.84 | 27.84 | 27.84 | 27.84 | 27.84 |
| Inventories | .0 | .0 | 10.5 | 15.0 | .0 | 3.0 | 3.9 | 5.0 | 6.5 | 8.5 |
| Inventories, % | 0.000048543689 | 0.000020920502 | 219.85 | 261.41 | 0 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | .3 | 2.1 | 8.4 | 2.4 | 1.5 | 3.4 | 4.4 | 5.7 | 7.4 | 9.6 |
| Accounts Payable, % | 13.01 | 44.27 | 175.35 | 41.97 | 26.29 | 45.11 | 45.11 | 45.11 | 45.11 | 45.11 |
| Capital Expenditure | -1.1 | -2.2 | -38.0 | -16.2 | -.9 | -4.7 | -6.1 | -7.9 | -10.2 | -13.3 |
| Capital Expenditure, % | -53.3 | -45.63 | -795.63 | -281.45 | -15.04 | -62.79 | -62.79 | -62.79 | -62.79 | -62.79 |
| Tax Rate, % | -0.09052559 | -0.09052559 | -0.09052559 | -0.09052559 | -0.09052559 | -0.09052559 | -0.09052559 | -0.09052559 | -0.09052559 | -0.09052559 |
| EBITAT | -6.5 | -13.9 | -97.8 | -103.9 | -109.6 | -7.3 | -9.5 | -12.3 | -16.0 | -20.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -7.1 | -14.5 | -133.3 | -117.7 | -82.9 | -7.8 | -9.3 | -12.1 | -15.8 | -20.5 |
| WACC, % | 13.73 | 13.73 | 13.7 | 13.73 | 13.73 | 13.72 | 13.72 | 13.72 | 13.72 | 13.72 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -42.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -21 | |||||||||
| Terminal Value | -178 | |||||||||
| Present Terminal Value | -94 | |||||||||
| Enterprise Value | -136 | |||||||||
| Net Debt | -56 | |||||||||
| Equity Value | -80 | |||||||||
| Diluted Shares Outstanding, MM | 92 | |||||||||
| Equity Value Per Share | -0.87 |
What You Will Receive
- Adjustable Forecast Parameters: Modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Actual Market Data: Absci Corporation’s financial figures pre-loaded to facilitate your analysis.
- Instant DCF Calculations: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Tailored and Professional: A refined Excel model that aligns with your valuation requirements.
- Designed for Analysts and Investors: Perfect for assessing projections, validating strategies, and enhancing efficiency.
Key Features
- Customizable Forecast Inputs: Adjust essential factors such as revenue growth, gross margin %, and research & development expenses.
- Instant DCF Valuation: Automatically computes intrinsic value, net present value (NPV), and additional metrics without delay.
- High-Precision Accuracy: Incorporates Absci Corporation's (ABSI) actual financial data for reliable valuation results.
- Effortless Scenario Analysis: Evaluate various assumptions and analyze results with ease.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the prebuilt Excel template featuring Absci Corporation’s (ABSI) data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalculated results, including Absci Corporation’s (ABSI) intrinsic value.
- Step 5: Make well-informed investment choices or create reports based on the outputs.
Why Choose This Calculator for Absci Corporation (ABSI)?
- All-in-One Solution: Offers DCF, WACC, and financial ratio analyses tailored for Absci Corporation.
- Adjustable Parameters: Modify yellow-highlighted fields to explore different financial scenarios.
- In-Depth Analysis: Automatically computes Absci’s intrinsic value and Net Present Value.
- Preloaded Information: Includes historical and projected data for precise calculations.
- Expert-Level Tool: Perfect for financial analysts, investors, and business consultants focusing on Absci Corporation.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for assessing Absci Corporation (ABSI) investments.
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Absci Corporation (ABSI) stock.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech firms like Absci Corporation (ABSI) are valued in the investment landscape.
What the Template Contains
- Pre-Filled DCF Model: Absci Corporation’s (ABSI) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Absci Corporation’s (ABSI) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.